SpaceX (SPCX US): SpaceX Soars in Historic IPO Debut, Closes Up 19% After Record-Breaking Raise
SpaceX (SPCX US) delivered a highly anticipated and successful public market debut, pricing its record-setting IPO at $135.00 per share and opening at $150.00, representing an immediate 11.1% gain at first trade. The offering consisted of 555.5 million shares, making it the largest IPO by cash proceeds ever completed, and investor demand proved capable of supporting the unprecedented scale.
Following the opening print, shares experienced steady institutional buying pressure throughout the morning session. During the first 90 minutes of trading, SPCX advanced consistently to an intraday high of $176.52, which ultimately stood as the high watermark for the session. Trading remained orderly throughout the day, with shares holding above volume-weighted average price (VWAP) for the majority of the session, reflecting sustained demand from long-term investors rather than speculative momentum-driven activity. Some profit taking emerged into the closing bell, though the stock still finished at a robust $160.95, representing a first-day gain of 19.2% from the IPO price.
Based on our channel checks, the demand profile was extraordinary. Sources indicate the institutional order book exceeded $250 billion, while retail demand surpassed $100 billion. Despite the significant retail interest generated by the Elon Musk association and SpaceX’s iconic brand, allocations were heavily skewed toward large global long-only institutions. We are told the retail tranche was ultimately reduced to approximately 20% of the offering.
Additionally, our sources state that more than 1,000 institutions participated in the book-building process, with approximately 10% of allocations awarded to international investors. Notably, the top 50 allocated accounts consisted almost exclusively of long-only asset managers, pension funds, and sovereign wealth funds. It is noteworthy that roughly one-third of participating accounts (who indicated for the deal) received no allocation at all. Discussions across our client base point to meaningful allocation cutbacks, further reinforcing the degree of oversubscription and demand concentration that characterized the transaction.
Investors should remain mindful of the company’s unique lockup provisions. Existing shareholders may sell up to 20% of their holdings beginning on the second full trading day following the release of the company’s first earnings report after the second quarter. In addition, an extra 10% of holdings may become eligible for sale if shares trade at least 30% above the IPO price for five of the ten trading days preceding that earnings release.
Ultimately, SpaceX achieved what many market participants hoped for but few expected at this scale: a record-breaking capital raise, strong first-day appreciation and disciplined trading behavior. Whether shares can build upon those gains will likely depend on the market’s continued appetite for one of the most closely watched growth stories of the modern era.
Parabilis Medicines, Inc. (PBLS): IPO Prices Above Range, Opens with Massive First-Day Pop
Parabilis Medicines (PBLS US) delivered a standout first trading session, pricing its IPO well above expectations and immediately translating that strength into a sharp aftermarket rally. The company priced 33.5 million shares at $20.00 per share, $1 above the top of its initially marketed $17–$19 range, signaling robust institutional demand in the final stages of bookbuilding. That strength carried directly into the first print, with shares opening at $33.35, representing a 66.8% gain at the open.
The stock hit a first day high of $34.02 before closing the session at $31.60.
The deal’s final pricing outcome reflected accelerating momentum in the pre-IPO phase. According to market sources, the offering was multiple-times oversubscribed, with estimates pointing to roughly 10x demand at peak indications. This level of oversubscription is particularly notable in the current biotech IPO environment, where selective risk appetite has made large, aggressively priced deals more difficult to execute. In Parabilis’ case, demand was strong enough not only to clear the top of the range, but also to justify an upsized offering ahead of launch—another key indicator of institutional conviction.
From a deal mechanics standpoint, Parabilis checked several boxes that often precede strong first-day performance: upwardly revised pricing, an upsized share count, deep oversubscription, and a high-quality syndicate backdrop. The combination of these factors created a supply-demand imbalance heading into the open, which manifested in the significant first-trade premium.
PBLS sold off a bit in its third session on Friday and closed the week at $27.26 but still significantly above its IPO price.
ERock Inc (EROC): Powering AI Story Meets Market Reality in Disappointing ERock Debut
ERock (EROC US) came to market on Wednesday, pricing its upsized IPO at $21.50 per share, the midpoint of the $20–$23 range, in a 27.9 million share offering. Despite what was described in pre-marketing as a multiple-times oversubscribed book and strong thematic positioning within AI-linked power infrastructure, the stock delivered a disappointing first-day performance, ultimately closing at $18.75 after a volatile and weak debut session.
Shares initially opened at $20.10, immediately marking a 6.5% decline from the offer price and setting a negative tone for trading. Selling pressure accelerated through the morning as investors aggressively de-risked positions, pushing the stock down to an intraday low of $17.89. The stock never reclaimed IPO pricing, ending the day firmly below the offer.
The underperformance stands out given the strength of ERock’s underlying narrative. The company sits squarely within one of the market’s most powerful secular themes: the accelerating demand for power to support AI data centers. ERock designs and deploys modular natural gas-based generation systems capable of providing rapid “speed-to-power” solutions in markets where utility interconnection delays can stretch multiple years.
EROC sank lower in its second and third sessions and closed the week at $16.95 or 21.1% below the issue price
WhiteHawk Minerals (WHK): Orderly Debut; Upsized IPO Prices at Midpoint, Ends Day at Issue Price
WhiteHawk Minerals (WHK US) completed its IPO at $26.00 per share, pricing 7.7 million shares after upsizing the offering from 6.9 million shares. The stock opened at $26.15, a modest +0.6% premium to the issue price, traded in a relatively tight $25.90-$26.50 range, and ultimately closed at the IPO price. Roughly 2.8 million shares traded hands on day one.
It should be noted that the IPO was originally scheduled for a Friday (6/5) debut, however, the company needed additional time to be “cleared” by the SEC which effectively happened on Monday (6/8).
WHK di rally throughout the week and closed Friday’ session at $27.29 or 4.9% above issue.
Forbright, Inc. (FRBT): Forbright Finishes Above Water After Shaky IPO Debut
Forbright (FRBT US) delivered a measured first-day performance following the pricing of its initial public offering, highlighting both the opportunities and challenges facing financial-sector issuers in today’s IPO market. The company priced its full-size offering of 7.9 million shares at $18.00 per share, the low end of its marketed $18-$20 range, raising approximately $142 million in gross proceeds. While the deal successfully crossed the finish line, the opening session underscored a market that remains highly valuation conscious when assessing bank and specialty finance offerings.
Shares opened at $17.50, representing an immediate decline of 2.8% from the IPO price. The stock spent the majority of its opening trading session below issue price, reflecting a cautious investor response despite the company’s attractive valuation metrics and specialized lending platform. For much of the day, the aftermarket lacked the momentum typically associated with stronger IPO debuts, suggesting that investors were willing to participate in the offering but were not eager to aggressively chase shares higher in secondary trading.
The stock closed Friday at $18.00.
Looking ahead, the IPO calendar remains active with two offerings scheduled to begin trading on Thursday, June 18: First Carolina Financial Services, Inc. and Kardigan, Inc..
First Carolina Financial Services is a diversified financial services company operating through a community banking platform and its BankMobile division, one of the largest digital banking and financial-services platforms focused on higher education in the United States.
Kardigan is a late-stage cardiovascular biotechnology company focused on developing novel therapies for serious heart diseases where treatment options remain limited or non-existent. The company’s lead programs include danicamtiv, an investigational cardiac myosin activator being developed for genetic dilated cardiomyopathy, along with additional late-stage cardiovascular assets targeting conditions with significant unmet medical need.